Trump chooses Dr. Mehmet Oz to lead Centers for Medicare and Medicaid Services

WASHINGTON — President-elect Donald Trump on Tuesday tapped Dr. Mehmet Oz, a former television talk show host and heart surgeon, to head the agency that oversees health insurance programs for millions of older, poor and disabled Americans.

“Dr. Oz will be a leader in incentivizing Disease Prevention, so we get the best results in the World for every dollar we spend on Healthcare in our Great Country,” Trump said in a statement. “He will also cut waste and fraud within our Country’s most expensive Government Agency, which is a third of our Nation’s Healthcare spend, and a quarter of our entire National Budget.”

Oz, who ran a failed 2022 bid to represent Pennsylvania in the U.S. Senate, has been an outspoken supporter of Trump and in recent days expressed support for Robert F. Kennedy Jr.’s nomination for the nation’s top health agency, the Department of Health and Human Services.

As the administrator for the Centers for Medicare and Medicaid Services, Oz would report to Kennedy. If confirmed by the Senate, Oz would be responsible for the programs — Medicaid, Medicare and the Affordable Care Act — that more than half the country relies on for health insurance. Medicaid provides nearly-free health care coverage to millions of the poorest children and adults in the U.S. while Medicare gives older Americans and the disabled access to health insurance. The Affordable Care Act is the Obama-era program that offers health insurance plans to millions of Americans who do not qualify for government-assisted health insurance, but do not get insurance through their employer.

“Americans need better research on healthy lifestyle choices from unbiased scientists, and @robertfkennedyjr can help as HHS secretary,” Oz shared in a post on Instagram last week, along with a photo of him and Kennedy together.

Oz has been accused of hawking dubious medical treatments and products on his defunct TV show. And during the height of the COVID-19 pandemic, he pressured government officials to make hydroxychloroquine widely available, despite unresolved questions about its safety and effectiveness.